CMS, ONC release Quality Data Model 4.1

The Centers for Medicare & Medicaid Services and the Office of the National Coordinator for Health Information Technology (ONC) announced the release of the Quality Data Model (QDM) 4.1.

The model describes clinical concepts in a standardized format to enable electronic clinical quality measurement, and “is the backbone for representing criteria used in quality measures that are currently used by stakeholders involved in electronic quality measurement development and reporting,” according to ONC.

The QDM 4.1 adds the following new operators and attributes, listed below:

  • Union and Intersection operators
  • Fulfills general relationship operator
  • Ends Concurrent With Start and Starts Concurrent With End timing operators
  • Medication, Order attributes: signed datetime and active datetime
  • Care Goal attribute: target outcome

It also includes the following modifications to the previous version of the specification:

  • Starts Before Or During renamed to Starts Before End
  • Ends Before Or During renamed to Ends Before End
  • Patient Characteristic Expired attribute reason renamed to cause
  • Measurement Start Date and Measurement End Date removed in favor of Measurement Period
  • Ambiguous and/or undefined datatypes/attributes clarified or removed (see QDM-46)
  • QDM data elements restricted to only one attribute at a time
  • Guidance provided regarding the topic of cumulative medication duration

Go here for more information.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.